Endocrine Abstracts

Glucagon-like peptide-1 receptor (GLP1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) have emerged as major drug targets for the treatment of type 2 diabetes and obesity. Drugs that target GLP1R and/or GIPR show profound effects on glucose levels, food intake and body weight. However, we still have limited knowledge of where GLP1R and GIPR are expressed in the body, which is holding back development of even more effective drugs. In the current presentation, I will introduce new technologies to visualize and interrogate GLP1R and GIPR expression from the single molecule to the whole animal. I will also discuss how these studies have led to new understanding of GLP1R and GIPR biology, with relevance for type 2 diabetes and obesity therapy, as well as ongoing clinical trials on neurodegenerative and inflammatory disease.